View Alert
Versions:


Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 14-Jun-2021 14:15:12. This version was issued on 14-Jun-2021 14:15:12

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • DHSC Supply Disruption - Medicines

Action category: Action

Title: Updated Publication of Remdesivir guidance for patients hospitalised with Covid-19 (adults and children aged 12 years and older)

Broadcast content: NHS trusts/health boards are advised to consider prescribing a course of remdesivir to eligible hospitalised patients with COVID-19 pneumonia, typically with dexamethasone as standard of care. This now includes re-admitted patients, patients with end-stage renal disease on haemodialysis and significantly immunocompromised patients, in line with the criteria in the updated NHS Interim Clinical Commissioning Policy. 

Additional information: This alert does not need to be cascaded to Primary Care

Alert reference: CEM/CMO/2021/013

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency